IP Library Granted Patent US 7,884,184
Granted Patent B2
US 7,884,184 · App. 12/021,832 · Granted Feb 8, 2011

Regulatory T cell epitopes, compositions and uses thereof

Assignee: Epivax, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,884,184
App. No.
12/021,832
Granted
Feb 8, 2011
Kind
B2
Abstract

The invention is directed to T cell epitopes wherein said epitopes comprises a peptide or polypeptide chain comprising at least a portion of an immunoglobulin constant or variable region. The invention also relates to methods of using and methods of making the epitopes of the invention.

Claims (21)

1. An isolated T-cell epitope polypeptide consisting of the sequence of SEQ ID NO: 5.

2. A pharmaceutical composition comprising the T-cell epitope polypeptide of claim 1 and a pharmaceutically acceptable carrier.

3. The pharmaceutical composition of claim 2 further comprising an effective amount of an antigen or allergen.

4. A method for expanding a population of regulatory T cells, comprising:

(a) providing a biological sample from a subject;

(b) isolating regulatory T-cells from the biological sample; and

(c) contacting the isolated regulatory T-cells with an effective amount of the T-cell epitope polypeptide of claim 1 under conditions wherein the T-regulatory cells increase in number to yield an expanded regulatory T-cell composition,

thereby expanding the regulatory T-cells in the biological sample.

5. A method for stimulating regulatory T cells in a biological sample, comprising:

(a) providing a biological sample from a subject;

(b) isolating regulatory T-cells from the biological sample; and

(c) contacting the isolated regulatory T-cells with an effective amount of the T-cell epitope polypeptide of claim 1 under conditions wherein the T-regulatory cells are stimulated,

thereby stimulating the regulatory T-cells in the biological sample.

6. A method of suppressing an antigen-specific immune response to a target antigen in a subject comprising administering to the subject a therapeutically effective amount of a composition comprising the T-cell epitope polypeptide of claim 1 , wherein the T-cell epitope polypeptide is either covalently bound, non-covalently bound or in admixture with the target antigen resulting in the diminution of immune response against the target antigen.

7. The method of claim 6 , wherein the suppressive effect is mediated by natural Treg.

8. The method of claim 6 , wherein the suppressive effect is mediated by adaptive Treg.

9. The method of claim 6 , wherein the suppresses T cell epitope polypeptide an effector T cell response.

10. The method of claim 6 , wherein the suppresses T cell epitope polypeptide a helper T cell response.

11. The method of claim 6 , wherein the suppresses T cell epitope polypeptide a B cell response.

12. A kit for repressing an antigen specific immune response in a subject, wherein the kit comprises a T-cell epitope polypeptide consisting of the sequence of SEQ ID NO: 5.

13. The kit of claim 12 , further comprising an effective amount of an antigen or allergen.

Assignments (2)
SECURITY INTEREST Recorded Jun 30, 2026
From: EPIVAX, INC.; EPV INTERMEDIATE HOLDINGS, LLC
To: FIFTH THIRD BANK, N.A.
Reel/Frame 075141/0047 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 13, 2009
From: RIVERA, DAN, MR.
To: EPIVAX, INC.
Reel/Frame 022261/0462 →
Continuity (2)
Provisional Application 60898347 · Jan 30, 2007
Related Publication 20090018067A1 · Jan 15, 2009